Maximus (MMS) Scheduled to Post Earnings on Wednesday

Maximus (NYSE:MMSGet Free Report) will announce its earnings results after the market closes on Wednesday, February 7th. Analysts expect the company to announce earnings of $1.28 per share for the quarter. Maximus has set its FY24 guidance at $5.05-5.35 EPS.Investors interested in listening to the company’s conference call can do so using this link.

Maximus (NYSE:MMSGet Free Report) last released its quarterly earnings data on Wednesday, November 15th. The health services provider reported $1.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by ($0.05). Maximus had a net margin of 3.30% and a return on equity of 14.46%. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the business earned $1.40 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts expect Maximus to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Maximus Trading Up 0.1 %

Shares of MMS opened at $83.96 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.46 and a current ratio of 1.46. The company’s fifty day moving average is $82.82 and its 200 day moving average is $80.41. The stock has a market capitalization of $5.12 billion, a PE ratio of 31.92 and a beta of 0.73. Maximus has a fifty-two week low of $71.65 and a fifty-two week high of $89.69.

Maximus Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 29th. Investors of record on Thursday, February 15th will be given a $0.30 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $1.20 dividend on an annualized basis and a yield of 1.43%. Maximus’s dividend payout ratio is currently 45.63%.

Insider Activity

In related news, insider Ilene R. Baylinson sold 10,043 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $85.57, for a total transaction of $859,379.51. Following the completion of the transaction, the insider now owns 5,002 shares of the company’s stock, valued at approximately $428,021.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Maximus

Several hedge funds have recently modified their holdings of MMS. International Assets Investment Management LLC grew its stake in shares of Maximus by 8,288.2% during the fourth quarter. International Assets Investment Management LLC now owns 1,426 shares of the health services provider’s stock worth $120,000 after buying an additional 1,409 shares during the last quarter. Toroso Investments LLC bought a new position in Maximus in the 3rd quarter worth approximately $265,000. Stifel Financial Corp boosted its holdings in Maximus by 3.6% in the 3rd quarter. Stifel Financial Corp now owns 11,152 shares of the health services provider’s stock worth $833,000 after buying an additional 391 shares during the period. Teachers Retirement System of The State of Kentucky boosted its holdings in Maximus by 10.1% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 10,897 shares of the health services provider’s stock worth $921,000 after buying an additional 997 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in Maximus by 36.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 543,289 shares of the health services provider’s stock valued at $45,913,000 after purchasing an additional 145,223 shares during the period. Institutional investors own 99.30% of the company’s stock.

Analysts Set New Price Targets

MMS has been the subject of a number of research analyst reports. cut Maximus from a “buy” rating to a “hold” rating in a report on Friday, January 12th. TheStreet raised Maximus from a “c+” rating to a “b-” rating in a research note on Monday, December 4th. Finally, Raymond James lowered Maximus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 3rd.

Get Our Latest Report on MMS

About Maximus

(Get Free Report)

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.

See Also

Earnings History for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with's FREE daily email newsletter.